Indicated for: type 2 diabetes mellitus
Route of administration: injectable
Substance: exenatide (GLP-1 receptor agonist)
ATC: A10BJ01 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Glucagon-like peptide-1 (GLP-1) analogues)
Exenatide is a medication used in the treatment of type 2 diabetes, classified as a GLP-1 (glucagon-like peptide-1) receptor agonist. It helps control blood sugar levels by stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and slowing gastric emptying, which lowers post-meal blood glucose levels.
Exenatide is available as an injectable solution and is administered either twice daily (immediate-release exenatide) or once weekly (extended-release exenatide). It is typically used in combination with other antidiabetic medications, such as metformin or sulfonylureas, when these alone are insufficient to control blood sugar. Additionally, exenatide may promote weight loss, an important benefit for overweight or obese patients with type 2 diabetes.
While effective, exenatide can cause side effects. The most common include nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. In rare cases, more serious reactions may occur, such as acute pancreatitis, hypoglycemia (especially when used with sulfonylureas), or severe allergic reactions. It is important for patients to inform their doctor of any unusual symptoms or side effects.
Exenatide should be used as directed by a doctor, and patients should be regularly monitored to assess the effectiveness of the treatment and detect potential side effects. It is contraindicated in patients with a history of pancreatitis, severe renal impairment, or hypersensitivity to the active substance. Patients are also advised to maintain a balanced diet and engage in regular physical activity to optimize blood sugar control.